SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

KPI-012

KALA·KALA BIO, Inc.
BEARISH
Drug Impact Rating1/10
Trial phase
Phase 2b (failed)
Time to market
Not stated
Why 1/10
KPI-012 failed its Phase 2b CHASE trial in September 2025 and development has been ceased. There are no scheduled catalysts for this drug. The company is pivoting to unrelated businesses. Impact score is minimal (1) because the drug is effectively dead with no further development path.
Actionable Insight BEARISH

KPI-012 development has been ceased after a Phase 2b failure. KALA BIO is pivoting to non-drug businesses (telehealth, genetic testing distribution, AI infrastructure). The next event is Q3 2026 earnings on November 17, 2026, but that will reflect the company's pivot, not KPI-012 progress. There are no further catalysts for this drug.

Price Chart

Loading chart...

Executive Summary

KPI-012 was KALA BIO's lead clinical-stage asset, a stem cell-derived therapy (human MSC-S) delivered as eye drops for Persistent Corneal Epithelial Defect (PCED), a rare eye condition. It received FDA Fast Track Designation in 2023. However, the Phase 2b CHASE trial failed in September 2025, missing the primary endpoint of complete corneal healing at Week 8, and KALA BIO ceased development of the drug. The stock collapsed roughly 92% on the news. KALA BIO (NASDAQ: KALA), now trading around $0.18, has been pivoting to unrelated businesses including a telehealth platform acquisition and genetic testing distribution. There are no remaining catalysts for KPI-012.

How It Works

KPI-012 is a stem cell-derived therapy (human mesenchymal stem cell secretome, or MSC-S). Instead of using live stem cells, it uses the proteins and factors that stem cells naturally secrete, applied as eye drops to promote healing of persistent defects in the cornea (the clear front surface of the eye).

Trial Status

The Phase 2b CHASE trial (multicenter, randomized, double-masked, placebo-controlled) completed enrollment in July 2025. Topline results announced September 29, 2025 showed the study did not meet the primary endpoint of complete healing of PCED at Week 8, and secondary endpoints also did not achieve statistical significance. KALA BIO ceased development of KPI-012 following the failure.

The Two-Sided Case

▲ Bull Case3
KPI-012 was well-tolerated in the Phase 2b trial with no treatment-related serious adverse events observed, suggesting a favorable safety profile.
The drug had received FDA Fast Track Designation in April 2023 for PCED, a rare and debilitating eye condition with no approved therapies addressing all underlying etiologies.
KALA BIO has been pivoting to new business lines (telehealth acquisition LOI, Virotek genetic testing distribution, AI infrastructure) but these are unrelated to KPI-012.
▼ Bear Case4
KPI-012 failed its Phase 2b CHASE trial in September 2025, missing the primary endpoint of complete healing of PCED at Week 8, with secondary endpoints also not reaching statistical significance.
KALA BIO announced it would cease development of KPI-012 after the failure, effectively ending the drug's clinical program.
The stock collapsed approximately 92% on the news, dropping from a 52-week high of $95.50 to around $0.18, reflecting near-total loss of value tied to this asset.
Analyst consensus is bearish: 0 Buy, 3 Hold, 1 Sell, 0 Strong Buy, 2 Strong Sell, with HC Wainwright (38% accuracy) and Oppenheimer (0% accuracy) both rated below average on the stock.

Upcoming Catalysts

  • None for KPI-012; development has been ceased.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

KALA BIO, Inc. 8-K KALA ·Originating report

Sources · 6

Hover a chip for the title
1 wwlp.com2 msn.com3 nasdaq.com4 wgno.com5 theglobeandmail.com6 theglobeandmail.com